Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$2.00 +1.5%	$1.80	$1.42 ▼ $12.33	$73.35M	1.4	594,869 shs	455,089 shs
MLSS Milestone Scientific	$0.97 -2.2%	$0.96	$0.58 ▼ $1.39	$76.36M	0.93	128,943 shs	64,310 shs
PTHL Pheton Holdings Ltd Class A Ordinary Shares	$5.70 -13.0%	$3.94	$1.32 ▼ $7.31	$37.52M	N/A	159,410 shs	1.37 million shs
ZYXI Zynex	$2.59 +8.4%	$2.26	$1.66 ▼ $10.62	$78.32M	0.7	161,585 shs	300,934 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	+1.52%	-6.10%	+6.95%	+1.01%	-81.82%
MLSS Milestone Scientific	-2.21%	-7.33%	-1.72%	+3.18%	+29.73%
PTHL Pheton Holdings Ltd Class A Ordinary Shares	-13.51%	+21.02%	+89.37%	+183.58%	+569,999,900.00%
ZYXI Zynex	+8.37%	+4.86%	+7.47%	-65.09%	-75.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INO Inovio Pharmaceuticals	3.8693 of 5 stars	3.3	2.0	0.0	4.3	3.4	0.0	1.3
MLSS Milestone Scientific	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTHL Pheton Holdings Ltd Class A Ordinary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	3.0255 of 5 stars	3.2	1.0	0.0	0.0	1.7	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	387.50% Upside
MLSS Milestone Scientific	3.00	Buy	$1.25	28.47% Upside
PTHL Pheton Holdings Ltd Class A Ordinary Shares	0.00	N/A	N/A	N/A
ZYXI Zynex	2.33	Hold	$6.00	131.66% Upside

Current Analyst Ratings Breakdown

Latest PTHL, MLSS, ZYXI, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
4/30/2025	ZYXI Zynex	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
4/30/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.00
4/15/2025	ZYXI Zynex	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform
3/19/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $5.00
3/19/2025	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/12/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $15.00
3/12/2025	ZYXI Zynex	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$11.00 ➝ $5.50
3/12/2025	ZYXI Zynex	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INO Inovio Pharmaceuticals	$283.10K	259.09	N/A	N/A	$5.16 per share	0.39
MLSS Milestone Scientific	$8.61M	8.86	N/A	N/A	$0.11 per share	8.85
PTHL Pheton Holdings Ltd Class A Ordinary Shares	$448.20K	83.71	N/A	N/A	N/A	∞
ZYXI Zynex	$172.40M	0.45	$0.14 per share	18.01	$1.36 per share	1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INO Inovio Pharmaceuticals	-$135.12M	-$3.19	N/A	N/A	N/A	N/A	-118.17%	-83.47%	8/14/2025 (Estimated)
MLSS Milestone Scientific	-$6.93M	-$0.07	N/A	∞	N/A	-52.01%	-60.26%	-40.23%	N/A
PTHL Pheton Holdings Ltd Class A Ordinary Shares	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	$9.73M	-$0.24	17.27	5.51	N/A	2.49%	13.05%	3.78%	7/23/2025 (Estimated)

Latest PTHL, MLSS, ZYXI, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
4/28/2025	Q1 2025	ZYXI Zynex	-$0.24	-$0.33	-$0.09	-$0.33	$30.83 million	$26.58 million
3/18/2025	Q4 2024	INO Inovio Pharmaceuticals	-$0.87	-$0.69	+$0.18	-$0.60	$0.03 million	$0.12 million
3/11/2025	Q4 2024	ZYXI Zynex	$0.09	-$0.02	-$0.11	-$0.02	$53.65 million	$45.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLSS Milestone Scientific	N/A	N/A	N/A	N/A	N/A
PTHL Pheton Holdings Ltd Class A Ordinary Shares	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INO Inovio Pharmaceuticals	N/A	3.88	3.88
MLSS Milestone Scientific	N/A	2.85	1.86
PTHL Pheton Holdings Ltd Class A Ordinary Shares	N/A	N/A	N/A
ZYXI Zynex	1.66	3.94	3.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INO Inovio Pharmaceuticals	26.79%
MLSS Milestone Scientific	5.79%
PTHL Pheton Holdings Ltd Class A Ordinary Shares	N/A
ZYXI Zynex	29.68%

Insider Ownership

Company	Insider Ownership
INO Inovio Pharmaceuticals	2.30%
MLSS Milestone Scientific	24.75%
PTHL Pheton Holdings Ltd Class A Ordinary Shares	N/A
ZYXI Zynex	49.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	25.45 million	Optionable
MLSS Milestone Scientific	30	78.48 million	58.61 million	Optionable
PTHL Pheton Holdings Ltd Class A Ordinary Shares	11	6.58 million	N/A	N/A
ZYXI Zynex	770	30.24 million	15.25 million	Optionable

PTHL, MLSS, ZYXI, and INO Headlines

Recent News About These Companies

Here’s Why Zynex (ZYXI) Fell in Q1

May 23, 2025 | msn.com

ZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens Berman

May 21, 2025 | morningstar.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex

May 21, 2025 | tmcnet.com

Zynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 ...

May 19, 2025 | gurufocus.com

Lost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class Action

May 19, 2025 | accessnewswire.com

Zynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff Motion

May 19, 2025 | globenewswire.com

ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit

May 19, 2025 | prnewswire.com

ZYXI Investors Have Opportunity to Lead Zynex, Inc. ...

May 19, 2025 | gurufocus.com

ZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. ...

May 19, 2025 | gurufocus.com

ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. ...

May 19, 2025 | gurufocus.com

ZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025

May 19, 2025 | accessnewswire.com

ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 19, 2025 | businesswire.com

ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 19, 2025 | globenewswire.com

ZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action – ZYXI

May 19, 2025 | globenewswire.com

Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending ...

May 19, 2025 | gurufocus.com

May 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZYXI

May 19, 2025 | globenewswire.com

Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXI

May 19, 2025 | prnewswire.com

Securities Lawsuit Alert: Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky Before May 19, 2025

May 19, 2025 | accessnewswire.com

May 19, 2025 Deadline: Join Class Action Lawsuit Against Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky

May 19, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI

May 19, 2025 | accessnewswire.com

HC Wainwright Issues Negative Estimate for Zynex Earnings

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL, MLSS, ZYXI, and INO Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

$2.00 +0.03 (+1.52%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.02 +0.02 (+0.75%)

As of 08:06 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Milestone Scientific NYSE:MLSS

$0.97 -0.02 (-2.21%)

Closing price 05/27/2025 03:57 PM Eastern

Extended Trading

$0.98 +0.01 (+0.82%)

As of 05/27/2025 04:04 PM Eastern

Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

Pheton Holdings Ltd Class A Ordinary Shares NASDAQ:PTHL

$5.70 -0.85 (-12.98%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.08 (+1.40%)

As of 08:00 AM Eastern

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

Zynex NASDAQ:ZYXI

$2.59 +0.20 (+8.37%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.58 0.00 (-0.19%)

As of 05/27/2025 07:00 PM Eastern

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time